Novo Nordisk, Obesity Drug

However, obesity specialists say some insurers have begun to require ... round of drugs that Medicare will negotiate for ...
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...
The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...